Vivos Therapeutics, Inc. Income Statement
VVOS|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Vivos Therapeutics, Inc. reported $15M in revenue and $11M in net loss for FY2025. Revenue has grown at a 5.7% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M |
| Cost of Revenue | $6.0M | $5.5M | $200.0K | $400.0K | $100.0K | - |
| Gross Profit | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M |
| SG&A Expense | $17.9M | $22.5M | $29.0M | $25.8M | $16.1M | $16.2M |
| R&D Expense | $100.0K | $100.0K | $200.0K | $200.0K | - | - |
| Operating Income | -$11.2M | -$17.3M | -$25.0M | -$20.4M | -$12.0M | -$10.6M |
| Interest Expense | $1.4M | - | - | $14.0K | $96.0K | $137.9K |
| Net Income | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M |
| EPS (Basic) | -$2.22 | -$11.14 | -$25.90 | -$0.96 | - | - |
| EPS (Diluted) | -$2.22 | -$11.14 | -$25.90 | - | -$1.40 | -$0.95 |
| Shares Outstanding | 5.9M | 1.8M | 920.6K | 23.0M | 18.2M | 12.4M |
| Gross Margin | 60.0% | 59.9% | 62.5% | 74.7% | 79.7% | 76.0% |
| Operating Margin | -74.3% | -125.3% | -156.2% | -120.7% | -92.2% | -92.8% |
| Profit Margin | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% | -94.4% |